Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases

CONCLUSION: There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.PMID:38563202 | DOI:10.1080/03009742.2024.2327159

Source: Scandinavian Journal of Rheumatology - April 2, 2024 Category: Rheumatology Authors: M Ayano K Tsubouchi K Suzuki Y Kimoto Y Arinobu K Akashi T Horiuchi I Okamoto H Niiro Source Type: research